medigraphic.com
ISSN 2221-2434 (Electronic)

2012, Number 1

<< Back Next >>

Finlay 2012; 2 (1)

Five Years Survival in Patients Operated from Malignant Neoplasm of Colon and Rectum

Guerra PEA, Torres AL, Domínguez SJE, Bernal MJL, Gastón AC

Language: Spanish
References: 20
Page: 8-15
PDF size: 444.07 Kb.


ABSTRACT

Background: Colorectal cancers include those cancers located in the large intestine, which is anatomically divided into colon and rectum. Especially those of epithelial type, currently represent a major health problem and a major mortality cause worldwide. Objective: To assess survival after five years in patients operated from colorectal cancer. Methods: An ambiespective and descriptive study was conducted with 108 patients operated from colorectal cancer at the Dr. Gustavo Aldereguía Lima Hospital of Cienfuegos in a 2 years period. The variables studied were: age, sex, tumor location, histological differentiation, clinical stages of tumor, surgical technique, use of chemotherapy and survival at five years. Results: The overall survival was of 66.7 % at five years, and stages I and IIb presented the highest survival, with 81% to 77 %. In general, females predominated (59.2 %) over males (40.7 %) and improved survival was observed throughout the period in women in a 70 % over men in a 62 %. Conclusions: Overall survival of patients at five years reported figures higher than those obtained in U.S., Europe and in the province of Cienfuegos in previous years, being the rectum the most common location showing also the best cumulative survival at five years with a 72 %.


REFERENCES

  1. American Cancer Society. Cancer Facts and Figures 2009[Internet]. Atlanta: American Cancer Society; 2009[citado: 10 Dic 2011]. Disponible en: http:// o r a l c a n c e r f o u n d a t i o n . o r g / f a c t s / p d f / Us_Cancer_Facts.pdf.

  2. Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray T. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99 (18):1384-94.

  3. National Cancer Institute. Colon and Rectum. In: SEER Cancer Statistics Review 1973-1999[Internet]. Bethesda: National Cancer Institute. Division of Cancer Control and Population Sciences; 2002[citado: 10 Dic 2011]. Disponible en: http://seer.cancer.gov/ csr/1973_1999/colorect.pdf. www.revfinlay.sld.cu Revista Finlay. 2012 Ene-Mar;2(1): Pág.15 REVISTA FINLAY (sobre enfermedades no transmisibles) ISSN 2221-2434

  4. Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al. EUROCARE- 3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14 Suppl 5:v128-49.

  5. Kauh J, Brawley OW, Berger M. Racial disparities in colorectal cancer. Curr Probl Cancer. 2007;31(3): 123- 33.

  6. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22(2):183-9.

  7. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57(3):168-85.

  8. DeVita VT, Hellman S, Rosenberg SA, DePhino RA, Weinberg RA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2008.

  9. Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control. 2005;16(3):201- 13.

  10. Young J, Jenkins M, Parry S, Young B, Nancarrow D, English D et al. Serrated pathway colorectal cancer in the population: genetic consideration. Gut. 2007;56 (10):1453-9.

  11. Locker GY, Kaul K, Weinberg DS, Gatalica Z, Gong G, Peterman A. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006;169(1):33-8.

  12. Schmidt CR, Gollub MJ, Weiser MR. Contemporary imaging for colorectal cancer. Surg Oncol Clin N Am. 2007;16(2):369-88.

  13. Siddiqui AA, Fayiga Y, Huerta S. The role of endoscopic ultrasound in the evaluation of rectal cancer. Int Semin Surg Oncol. 2006;3:36.

  14. Søreide K. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time? Tumour Biol. 2007;28(5):290-300.

  15. Zammit M, Jenkins JT, Urie A, O'Dwyer PJ, Molloy RG. A technically difficult endorectal ultrasound is more likely to be inaccurate. Colorectal Dis. 2005;7(5):486- 91.

  16. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338-51.

  17. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9):1750-5.

  18. Lahaye MJ, Engelen SM, Nelemans PJ, Beets GL, van de Velde CJ, van Engelshoven JM, et al. Imaging for predicting the risk factors -the circumferential resection margin and nodal disease- of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR. 2005;26(4):259-68.

  19. Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol. 2006;12(20):3186-95.

  20. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014-20. 21.Lai LL, Fuller CD, Kachnic LA, Thomas CR. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol. 2006;33(6 Suppl 11):S70- 4.




2020     |     www.medigraphic.com